Received Notice of Approval for Drug Clinical Trial
January 21, 2026
Source: drugdu
28
Hengrui Pharma announced on January 20, 2026, that the company and its subsidiaries, Suzhou Shengdia Biopharmaceutical Co., Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd., have received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration (NMPA) for SHR-9839 for Injection (sc) and HRS-4642 Injection. Clinical trials for these drugs will commence in the near future. Additionally, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the "Notice of Approval for Drug Clinical Trial" from the NMPA for HRS-2141 Tablets (I) and (II), and will also begin clinical trials shortly.
https://finance.eastmoney.com/a/202601203624765352.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Phase III Clinical Trial of Recombinant Staphylococcus Aureus Vaccine Progressing Normality January 21, 2026
- Its drug marketing application for injectable iza-bren has been accepted January 21, 2026
- Kain Technology withdrew a drug registration application, resulting in a profit reduction of 111 million yuan in 2025 January 21, 2026
- Breaking news! AstraZeneca to be delisted from Nasdaq. January 21, 2026
- XinYue Bio Secures Tens of Millions in Series A+ Follow-on Funding to Advance DEL+AI-Powered Drug Discovery January 21, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
